Prostate cancer Board decisions

The Veteran withdrew his appeals for the claims of service connection for prostate cancer, erectile dysfunction, and urinary incontinence. As a result, these issues are dismissed.

The Veteran's claim for service connection for prostate cancer was received by VA on April 15, 2022. The Board granted the claim and assigned an effective date of April 15, 2022.

The Veteran's prostate cancer is granted as a result of in-service herbicide exposure. The bilateral ankle disorder claim is remanded due to duty to assist error.

The Board has granted service connection for prostate cancer and a reproductive system disorder (urinary incontinence and erectile dysfunction) as secondary to the now-service-connected prostate cancer, based on presumed exposure to Agent Orange during service.

The Board has remanded the Veteran's claims for prostate cancer and erectile dysfunction, including as secondary to prostate cancer. The decision is pending further development of his service records and verification of herbicide exposure.

The Board has decided to remand the Veteran's claim for prostate cancer as there is insufficient evidence regarding his exposure claims and further development is needed.

The Veteran's prostate cancer, metastatic bone cancer, and metastatic lymph node cancer are all granted service connection for purposes of accrued benefits.

The Veteran's brain tumor, which caused his death in July 2014, is granted service connection based on presumed exposure to herbicide agents during service. The Veteran's prostate cancer and enlarged prostate are denied service connection.

The Board has remanded the Veteran's claims for service connection due to insufficient evidence regarding his in-service toxic exposures. The issues of type II diabetes mellitus, hypertension, prostate cancer, and thyroid disability are being remanded for further development.

The Board denied service connection for prostate cancer as there was no evidence linking the condition to service, including exposure to contaminated water at Camp Lejeune.

The Veteran's PTSD is granted at a 100 percent evaluation, and he is also awarded SMC based on the need for aid and attendance due to his service-connected disabilities. The issue of TDIU is dismissed as moot.

The Board has determined that the claim of entitlement to service connection for prostate cancer must be readjudicated based on new and relevant evidence. The case is REMANDED for further development by the AOJ.

The Veteran's service connection claims for coronary artery disease, diabetes mellitus type II, Parkinson's disease, prostate cancer, and chronic kidney disease due to herbicide agent exposure are all granted.,Service connection is also granted for hypertension under the PACT Act.

The Board has remanded the Veteran's claims for service connection for bilateral hearing loss, prostate cancer (due to contaminated water exposure at Camp Lejeune), erectile dysfunction, and overactive bladder. The claims are being remanded due to a lack of current evidence supporting these conditions.

The Board has remanded the Veteran's claims for service connection due to a lack of evidence and because he did not provide private treatment records or attend his VA examinations. The Veteran was exposed to herbicide agents in Vietnam, but missed his VA examinations.

The Veteran's appeals for hypertension, diabetes mellitus, type II (DMII), and prostate cancer have been dismissed due to his death. The Board has no jurisdiction to adjudicate the merits of these claims as he died during the pendency of the appeal.

The Board has granted service connection for bilateral hearing loss and remanded the issues of increased evaluations for prostate cancer, erectile dysfunction, and SMC for loss of creative organ.

The Board has granted service connection for prostate cancer and ischemic heart disease (including coronary artery disease, myocardial infarction, status post coronary stenting, and congestive heart failure) due to presumed exposure to herbicide agents during the Veteran's deployment in Korea.

The appeal to reduce the disability rating for prostate cancer from 100% to 20% is dismissed as a matter of law because the April 2020 proposed reduction was not a final agency action.

The Veteran's liver disability is not rated higher than the current 0 percent rating due to lack of specific symptoms warranting a higher rating.,The Veteran's unspecified anxiety disorder does not meet the criteria for a higher than 30 percent rating based on his symptoms and occupational/social impairment.,The Veteran's prostate cancer, currently rated at 40 percent, does not meet the criteria for a higher than 40 percent rating due to lack of specific symptoms warranting such an increase.